Surviving Childhood Cancer Increase Risk of Heart Disease in Adulthood

Those who survive cancer as children are shown to be at greater risks of heart problems in early adulthood:

"Children and young people who survive cancer have a significantly higher risk of developing heart disease as young adults because of the cancer treatment they received, researchers said Wednesday.

A study by doctors from the United States found that young adult survivors of childhood cancer are at risk of a range of cardiac problems such as heart failure, heart attacks, or heart disease and the risks continued up to 30 years after treatment.

"Young adults who survive childhood or adolescent cancer are clearly at risk for early cardiac morbidity and mortality not typically recognized within this age group," said Daniel Mulrooney from the University of Minnesota, who led the study."

Read More: http://www.canada.com/life/diversions/games/badapple/Child+cancer+surviv...

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap